The manufacturing enterprise "Akademfarm" offers consumers the antihypertensive drug "Nebivolol-NAN" - a highly selective third-generation β1-adrenergic blocker that has an additional vasodilatory effect under a manufacturing agreement and is looking for partners to conclude a distribution services agreement.

Antihypertensive medications are produced by leading global pharmaceutical corporations from the USA, Switzerland, France, Germany, and Japan, setting standards for hypertension treatment and developing innovative original molecules and fixed-dose combinations.

Key global manufacturers:

1. Pfizer (USA): The company revolutionized hypertension treatment with the creation of amlodipine (original brand name "Norvasc"), the "gold standard" among calcium channel blockers. These products are distinguished by their high bioavailability, predictable therapeutic effect, and minimal risk of sudden blood pressure spikes.
2. Novartis (Switzerland): The company's primary focus is blocking the renin-angiotensin-aldosterone system (RAAS). They developed the molecule valsartan (Diovan), which forms the basis of most modern combination medications that reduce the risk of strokes and heart attacks.
3. Sanofi (France): The company's products are focused on individualized therapy for various patient groups, including the elderly and those with metabolic syndrome. The irbesartan-based line (Aprovel) has demonstrated a powerful nephroprotective effect (kidney protection in diabetes).
4. Boehringer Ingelheim (Germany): Manufacturer of the original telmisartan (Micardis), an antihypertensive agent with the longest half-life (over 24 hours). This ensures reliable blood pressure control during the dangerous early morning hours.
5. Servier (France): A historical leader in the ACE inhibitor class thanks to the perindopril molecule. The company actively promotes the "Single Pill Combination" concept, combining an ACE inhibitor, a diuretic, and a calcium antagonist in a single capsule, dramatically improving patient adherence.

Nebivolol-NAN, manufactured by Akadempharm, is a highly selective third-generation β1-adrenergic blocker with additional vasodilatory properties. It is used to treat hypertension and heart failure.

You can download information about Nebivolol-NAN from the company's official website here.

In-house production. Highly qualified personnel.

International nonproprietary name: Nebivolol

The Republican production unitary enterprise "ACADEMPHARM" is a dynamically developing, science-intensive state-owned pharmaceutical company. Despite its young age in the pharmaceutical industry, "ACADEMPHARM" has already carved out a niche in the domestic market and continues to expand. The company focuses on unmet medical needs, expanding its product range annually.

Activities:
- Laboratory pharmaceutical research;
- Industrial production of medicinal products and other pharmaceuticals, vitamins, vitamin-mineral and metabolic complexes, and nutraceuticals;
- Contract pharmaceutical manufacturing.

Production lines are equipped with the latest equipment from leading global companies, meeting all GMP requirements.

The pharmaceutical quality system includes good manufacturing practices, quality control, and quality risk management. It is fully documented, and its effectiveness is monitored. All components of the quality system are staffed with competent personnel, sufficient facilities, equipment, and technical resources.

Official website of the Enterprise "Academpharm".

The Republican production unitary enterprise "AKADEMPHARM" holds national GMP (Good Manufacturing Practice) certificates for the production of all forms of its own products.

The company has implemented and operates a pharmaceutical quality system developed in accordance with the requirements of the national standard TKP 030-2017 (33050) "Good Manufacturing Practice" and international requirements.

Consumers interested in purchasing an antihypertensive drug "Nebivolol-NAN" is a highly selective third-generation β1-adrenergic blocker with additional vasodilatory properties under a manufacturing agreement.

Partners interested in purchasing an antihypertensive drug "Nebivolol-NAN" is a highly selective third-generation β1-adrenergic blocker with additional vasodilatory properties under a distribution services agreement.